GlassScriptPhysician profile
Todd R Shepler
NPI 1568453447
$3,736.45
in general payments reported to CMS, 2019-2025
24 companies · $275 in 2025
The $275 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $851 · 2020: $479 · 2021: $602 · 2022: $459 · 2023: $527 · 2024: $544 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,346.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $888.92 | 2019-2025 | Lumigan, Alphagan P, Vuity |
| Allergan, INC. | $580.22 | 2019-2022 | |
| Biotissue Holdings INC. | $347.03 | 2019-2024 | |
| Aerie Pharmaceuticals, INC. | $260.55 | 2019-2020 | |
| Horizon Therapeutics Plc | $244.67 | 2019-2023 | Tepezza |
| Ocular Therapeutix, INC. | $187.34 | 2020-2023 | Dextenza |
| Johnson & Johnson Surgical Vision, INC. | $176.46 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $142.66 | 2024 | Xdemvy |
| Mallinckrodt Enterprises LLC | $119.31 | 2019 | |
| Bausch & Lomb Americas INC. | $108.41 | 2023-2025 | Vyzulta, Miebo, Xiidra |
| Novartis Pharmaceuticals Corporation | $103.21 | 2021-2023 | |
| Optovue, INC. | $100.00 | 2019 | |
| Optos, INC. | $98.66 | 2021 | |
| Sun Pharmaceutical Industries INC. | $89.86 | 2020-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $85.58 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $56.32 | 2021-2024 | Rocklatan |
| Amgen INC. | $28.38 | 2025 | Tepezza |
| Astellas Pharma US INC | $23.56 | 2024 | Izervay |
| Oyster Point Pharma, INC. | $20.44 | 2025 | Tyrvaya, Ryzumvi |
| Harrow Eye, LLC | $18.94 | 2024 | Vevye |
| Carl Zeiss Meditec, INC. | $17.03 | 2021 | |
| Rxsight INC | $13.99 | 2022 | |
| Mallinckrodt Hospital Products INC. | $12.46 | 2022 | |
| Kala Pharmaceuticals, INC. | $12.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Shepler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.